Gossamer Bio (GOSS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $8.77, -1.35% vs the prior close of $8.89.
- Volume 171.01K shares, 0.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
GOSS dips 1.3% to $8.77, a 52-week low, 3 down days in a row. Closed at $8.77, -1.35% vs the prior close of $8.89. Day range $8.51–$8.99, opened at $8.99.
GOSS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — GOSS dips 1.3% to $8.77, a 52-week low, 3 down days in a row
- Closed at $8.77, -1.35% vs the prior close of $8.89. Day range $8.51–$8.99, opened at $8.99.
- Volume was 171.01K shares, 0.6x its 50-day average of 282.11K.
- Price is -26.5% vs its 50-day average ($11.93) and -82.9% vs its 200-day average ($51.26).
- 52-week range $8.51–$309.60; today's close sits at 0% of that range, 97.2% below the 52-week high.
- That makes 3 straight losses.
Oct 15, 2026 — GOSS ends flat (-0.2%) to $8.89, a 52-week low
- Closed at $8.89, -0.17% vs the prior close of $8.90. Day range $8.73–$9.18, opened at $8.86.
- Volume was 197.70K shares, 0.7x its 50-day average of 280.16K.
- Price is -26.2% vs its 50-day average ($12.04) and -83.1% vs its 200-day average ($52.46).
- 52-week range $8.73–$309.60; today's close sits at 0% of that range, 97.1% below the 52-week high.
Oct 14, 2026 — GOSS slides 8.8% to $8.90, a 52-week low
- Closed at $8.90, -8.76% vs the prior close of $9.76. Day range $8.77–$9.64, opened at $9.59.
- Volume was 360.80K shares, 1.3x its 50-day average of 276.64K.
- Price is -26.7% vs its 50-day average ($12.15) and -83.4% vs its 200-day average ($53.70).
- 52-week range $8.77–$309.60; today's close sits at 0% of that range, 97.1% below the 52-week high.
Oct 13, 2026 — GOSS jumps 5.2% to $9.76
- Closed at $9.76, +5.17% vs the prior close of $9.28. Day range $9.26–$10.03, opened at $9.83.
- Volume was 478.00K shares, 1.8x its 50-day average of 271.50K.
- Price is -20.4% vs its 50-day average ($12.26) and -82.2% vs its 200-day average ($54.95).
- 52-week range $8.99–$309.60; today's close sits at 0% of that range, 96.8% below the 52-week high.
Oct 12, 2026 — GOSS dips 0.3% to $9.28, a 52-week low, 4 down days in a row
- Closed at $9.28, -0.32% vs the prior close of $9.31. Day range $8.99–$9.54, opened at $9.54.
- Volume was 155.00K shares, 0.6x its 50-day average of 274.81K — lighter than usual.
- Price is -24.8% vs its 50-day average ($12.34) and -83.5% vs its 200-day average ($56.27).
- 52-week range $8.99–$309.60; today's close sits at 0% of that range, 97.0% below the 52-week high.
- That makes 4 straight losses.
Oct 9, 2026 — GOSS slides 5.8% to $9.31, a 52-week low, 3 down days in a row
- Closed at $9.31, -5.77% vs the prior close of $9.88. Day range $9.20–$10.10, opened at $9.93.
- Volume was 289.90K shares, 1.0x its 50-day average of 276.67K.
- Price is -25.1% vs its 50-day average ($12.43) and -83.8% vs its 200-day average ($57.54).
- 52-week range $9.12–$309.60; today's close sits at 0% of that range, 97.0% below the 52-week high.
- That makes 3 straight losses.
Oct 8, 2026 — GOSS dips 2.9% to $9.88, a 52-week low
- Closed at $9.88, -2.95% vs the prior close of $10.18. Day range $9.66–$10.28, opened at $10.02.
- Volume was 196.80K shares, 0.7x its 50-day average of 280.30K.
- Price is -21.1% vs its 50-day average ($12.53) and -83.3% vs its 200-day average ($59.00).
- 52-week range $9.12–$309.60; today's close sits at 0% of that range, 96.8% below the 52-week high.
Oct 7, 2026 — GOSS slides 5.6% to $10.18, a 52-week low
- Closed at $10.18, -5.57% vs the prior close of $10.78. Day range $9.77–$10.66, opened at $10.38.
- Volume was 280.60K shares, 0.9x its 50-day average of 327.49K.
- Price is -19.6% vs its 50-day average ($12.66) and -83.1% vs its 200-day average ($60.33).
- 52-week range $9.12–$309.60; today's close sits at 0% of that range, 96.7% below the 52-week high.
Oct 6, 2026 — GOSS rises 1.2% to $10.78
- Closed at $10.78, +1.22% vs the prior close of $10.65. Day range $10.50–$10.93, opened at $10.77.
- Volume was 196.60K shares, 0.5x its 50-day average of 412.84K — lighter than usual.
- Price is -15.7% vs its 50-day average ($12.79) and -82.5% vs its 200-day average ($61.65).
- 52-week range $9.12–$309.60; today's close sits at 1% of that range, 96.5% below the 52-week high.
Oct 5, 2026 — GOSS dips 0.6% to $10.65, 3 down days in a row
- Closed at $10.65, -0.56% vs the prior close of $10.71. Day range $10.00–$10.99, opened at $10.70.
- Volume was 390.90K shares, 1.0x its 50-day average of 407.75K.
- Price is -17.4% vs its 50-day average ($12.89) and -83.1% vs its 200-day average ($63.02).
- 52-week range $9.12–$309.60; today's close sits at 1% of that range, 96.6% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — GOSS dips 2.0% to $10.71
- Closed at $10.71, -2.01% vs the prior close of $10.93. Day range $10.19–$11.19, opened at $11.19.
- Volume was 235.00K shares, 0.6x its 50-day average of 406.55K — lighter than usual.
- Price is -16.9% vs its 50-day average ($12.89) and -83.4% vs its 200-day average ($64.40).
- 52-week range $9.12–$309.60; today's close sits at 1% of that range, 96.5% below the 52-week high.
GOSS latest news & SEC filings
Every SEC filing by or about GOSS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 28, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 16, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Sep 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.03 — Change to shareholder rights.
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 8.01 — Reported other events the company considers important.
Sep 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade GOSS
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: Jul 27, 2026, May 18, 2026, Mar 17, 2026. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.26% (largest 8.8%). That is a volatile stock.
- Liquidity: about 307.87K shares (≈$2.70M) trade per day on average.
- 52-week position: $8.77 vs a range of $8.51–$309.60 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:80 on Sep 11, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 28, 2026; 8-K Sep 23, 2026; 8-K Sep 16, 2026.
- Share count: 488.85M shares outstanding (Aug 8, 2026), +115.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
GOSS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 8.99 | 8.99 | 8.51 | 8.77 | 171.01K |
| Oct 15, 2026 | 8.86 | 9.18 | 8.73 | 8.89 | 197.70K |
| Oct 14, 2026 | 9.59 | 9.64 | 8.77 | 8.90 | 360.80K |
| Oct 13, 2026 | 9.83 | 10.03 | 9.26 | 9.76 | 478.00K |
| Oct 12, 2026 | 9.54 | 9.54 | 8.99 | 9.28 | 155.00K |
| Oct 9, 2026 | 9.93 | 10.10 | 9.20 | 9.31 | 289.90K |
| Oct 8, 2026 | 10.02 | 10.28 | 9.66 | 9.88 | 196.80K |
| Oct 7, 2026 | 10.38 | 10.66 | 9.77 | 10.18 | 280.60K |
| Oct 6, 2026 | 10.77 | 10.93 | 10.50 | 10.78 | 196.60K |
| Oct 5, 2026 | 10.70 | 10.99 | 10.00 | 10.65 | 390.90K |
| Oct 2, 2026 | 11.19 | 11.19 | 10.19 | 10.71 | 235.00K |
| Oct 1, 2026 | 11.63 | 12.14 | 10.80 | 10.93 | 351.80K |
| Sep 30, 2026 | 11.53 | 12.46 | 11.16 | 11.85 | 381.90K |
| Sep 29, 2026 | 11.68 | 11.85 | 11.21 | 11.58 | 384.00K |
| Sep 28, 2026 | 10.46 | 11.85 | 10.33 | 11.52 | 516.40K |
| Sep 25, 2026 | 10.93 | 11.01 | 10.22 | 10.94 | 426.60K |
| Sep 24, 2026 | 10.76 | 11.68 | 10.75 | 10.93 | 236.10K |
| Sep 23, 2026 | 11.69 | 11.97 | 10.03 | 10.99 | 453.80K |
| Sep 22, 2026 | 11.48 | 12.31 | 11.35 | 11.69 | 195.60K |
| Sep 21, 2026 | 11.60 | 11.94 | 10.91 | 11.28 | 258.80K |
About Gossamer Bio
Gossamer Bio (GOSS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1728117.
GOSS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Gregory Austin Ciongoli | Director | Sep 25, 2026 |
| Russell J. Cox | Director | Sep 25, 2026 |
| Thomas O Daniel | Director | Sep 25, 2026 |
| Skye Drynan | Director | Sep 25, 2026 |
| Faheem Hasnain | President & CEO | Aug 26, 2026 |
| Sandra Milligan | Director | Sep 25, 2026 |
| Steven D Nathan | Director | Sep 25, 2026 |
| John D Quisel | Director | Sep 25, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Richard Aranda | Chief Medical Officer | Mar 20, 2026 |
| Waage Christian | EVP, Tech Ops and Admin | Aug 26, 2026 |
| Bryan Giraudo | COO/CFO | Aug 26, 2026 |
| Faheem Hasnain | President & CEO | Aug 26, 2026 |
| Caryn Peterson | Chief Development Officer | Aug 26, 2026 |
| Robert Paul Jr Smith | Chief Commercial Officer | Aug 26, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
GOSS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $48.47M | $-170.37M | -0.75 | $-171.27M |
| Dec 31, 2024 | $114.70M | $-56.53M | -0.25 | $-3.47M |
| Dec 31, 2023 | $0 | $-179.82M | -1.18 | $-159.16M |
| Dec 31, 2022 | $0 | $-229.38M | -2.71 | $-187.03M |
| Dec 31, 2021 | — | $-234.00M | -3.13 | $-188.89M |
Latest balance sheet: total assets $76.87M, total liabilities $170.90M, cash $41.15M (as of Jun 30, 2026).
GOSS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $13.60 |
| Jul 27, 2026 | 8-K Item 2.02 (results) | $15.92 |
| May 18, 2026 | 8-K Item 2.02 (results) | $15.44 |
| Mar 17, 2026 | 8-K Item 2.02 (results) | $37.76 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $189.60 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $172.80 |
| May 15, 2025 | 8-K Item 2.02 (results) | $84.00 |
| Mar 13, 2025 | 8-K Item 2.02 (results) | $104.00 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $70.96 |
| Aug 12, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Mar 5, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on GOSS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.